A Study of LY3439539 in Participants With Alzheimer's Disease

Part of paid clinical trials in Irvine, California.

Sponsor
Eli Lilly and Company
Study ID
NCT07598370
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • LY3439539 — DRUG
    Administered IV

Study Details

The purpose of this study is to see how LY3439539 affects certain proteins found in the spinal fluid of participants with Alzheimer's disease. Participation in the study will last approximately 9 months with visits about once a month.

Key Dates

First listed
May 20, 2026
Start date
May 21, 2026
Status verified
Jul 2026
Primary completion
Aug 31, 2027
Completion
Aug 31, 2027

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: LY3439539
    LY3439539 administered intravenously (IV)

Primary Outcome Measure

Change from Baseline in Cerebrospinal Fluid (CSF) Neurofilament Light Chain (NfL) [ Time Frame: Baseline through end of the Follow-up Period (Week 24) ]

Central Contacts

  • Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
    1-317-615-4559
    [email protected]
  • Physicians interested in becoming principal investigators please contact
    [email protected]

Locations (1)

FacilityCityStateZIPSite coordinators
Irvine Clinical ResearchIrvineCalifornia92614
949-753-1663
Elly Lee (PRINCIPAL_INVESTIGATOR)

Find similar trials in Irvine, CA

By condition
Alzheimer's disease
By specialty
NeurologyDementia careBrain disordersGeriatrics
By research site
Irvine Clinical Research· Irvine, CA

Related Studies